Under the deal, the OCTC will provide integrated research, clinical trial and core lab services, while Bryla will provide commercialization services in chemistry, manufacturing and control (CMC).
Bryla CMC-Reg Consulting president Piotr Bryla said: "Our co-marketing relationship with the OCTC creates a unique opportunity for Bryla CMC-Reg Consulting to advance science and clinical research for new investigational drugs in various therapeutics areas through the OCTC and its academic and industry networks."
OCTC Global Business Development executive director John Peterson said: "I have strong aspirations for this partnership in providing synergy in support of our research and clinical networks coupled with Bryla’s commercialization process."
The deal will see OCTC provide its industry partners with translational science research support in areas such as genetics, protein, RNA and DNA sciences, proteomics, metabolomics, regenerative medicine, stem cells, and basic medical sciences for all diseases.
Additionally, the OCTC offers access to its research and clinical networks for partners of Bryla CMC-Reg Consulting.
Bryla CMC-Reg has an existing partnership with TeraCrystal, a solid-state chemistry lab, to provide services in pre-formulation, solid state chemistry and crystal engineering experimental support.
According to OCTC, its clients will be able to access this expertise through Bryla CMC-Reg Consulting.